A Phase 2 interventional study of RO7268489 and Ocrelizumab in Progressive Multiple Sclerosis, sponsored by Hoffmann-La Roche. Recruiting at 114 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche — 2 open to participants now, 8 under way, 4 of them phase 3. Multiple Sclerosis, Chronic Progressive · Hoffmann-La Roche.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 2, and was the 9th registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →2 of the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
By country, each count listing its studies:
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 400 across the 12 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.
Drug: RO7268489 · Drug: Ocrelizumab
Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.
Drug: RO7268489 · Drug: Ocrelizumab
Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.
Drug: RO7268489 · Drug: Ocrelizumab
Participants will receive RO7268489 matching placebo along with ocrelizumab as per the pre-defined regimen.
Drug: Ocrelizumab · Drug: Placebo
RO7268489 will be administered per schedule as specified in the arms.
Ocrelizumab will be administered per schedule as specified in the arms.
Also known as: RO4964913, Ocrevus
Placebo will be administered per schedule as specified in the arms.
Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)
Time from randomization to the first occurrence of cCDP12 according to at least one of the following 3 criteria: 1. 12-week confirmed disability progression (CDP12) 2. 12-week confirmed increase in Timed 25-Foot Walk Test (T25FWT) or 3. 12-week confirmed increase in 9-Hole Peg Test (9-HPT) The EDSS is a disability scale is based on a standard neurological examination that ranges in 0.5-point steps from 0 (normal) - 10 (death). T25FWT=time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. In 9-HPT, participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. The shorter time it takes to complete the task indicates a better outcome.
Time frame: Up to approximately 110 weeks
Time From Randomization to the First Occurrence of 24-Week Confirmed ≥4-Point Decrease (Worsening) in Symbol Digit Modalities Test (SDMT)
The SDMT is a performance measure of processing speed that is widely used to assess cognitive function in response to treatment. It's brief, easy to administer, and involves a simple substitution task that healthy children and adults can easily perform. Using a reference key, the participant has 90 seconds to pair specific numbers with given geometric figures. The total SDMT score is the total number of correct responses and ranges from 0 to 110, with a higher score indicating a higher level of processing speed. A four-point change from baseline is typically considered clinically meaningful.
Time frame: Up to approximately 110 weeks
Time to Onset of 24-Week cCDP (cCDP24)
Time frame: Up to approximately 110 weeks
Time to Onset of 12-Week Confirmed Disability Progression CDP (CDP12)
Time frame: Up to approximately 110 weeks
Time to Onset of 24-Week CDP (CDP24)
Time frame: Up to approximately 110 weeks
Time to ≥ 20% Increase in 12-week Confirmed Timed 25-Foot Walk Test (T25FWT)
The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.
Time frame: Up to approximately 110 weeks
Time to ≥ 20% Increase in 24-week Confirmed T25FWT
The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.
Time frame: Up to approximately 110 weeks
Time to ≥ 20% Increase in 12-week Confirmed 9-Hole Peg Test (9-HPT)
Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
Time frame: Up to approximately 110 weeks
Time to ≥ 20% Increase in 24-week Confirmed 9-HPT
Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, \& then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
Time frame: Up to approximately 110 weeks
Change From Baseline in Total Brain Volume
Time frame: Up to approximately 110 weeks
Plasma 2-arachidonoylglycerol (2-AG) Levels
Time frame: Up to approximately 110 weeks
Change From Baseline in Plasma 2-AG Levels
Time frame: Up to approximately 110 weeks
Number of Participants With Adverse events (AEs)
Time frame: Up to 5 years
Number of Participants With Treatment Discontinuations due to AEs
Time frame: Up to 5 years
Proportion of Participants With Suicidal Ideation or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.
Time frame: Up to 5 years
Plasma Concentrations of RO7268489 and Its Metabolite(s)
Time frame: Up to 5 years
Showing the first 100 of 114 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 26 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Chronic Progressive →